Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Phase 2

Active, not recruiting

Conditions: TNBC - Triple-Negative Breast Cancer
Triple Negative Breast Cancer
NSCLC
NSCLC Stage IV
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
NSCLC Stage IV Without EGFR/ALK Mutation

Interventions: Radiation: Sterotactic Body Radiotherapy/SBRT
Drug: Standard of care

First Posted Date: 2019-01-17

Last Posted Date: 2024-06-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 107

Registration Number: NCT03808662

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 7 locations

A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)

Active, not recruiting

Conditions: Multiple Ground Glass Opacities (GGOs)

First Posted Date: 2019-01-14

Last Posted Date: 2024-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 338

Registration Number: NCT03802981

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 29 locations

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

Not Applicable

Active, not recruiting

Conditions: Locally Advanced Cancer
Thoracic Cancer
Lymphoma
Metastatic Cancer
Gynecologic Cancer
Genitourinary Cancer

Interventions: Behavioral: Weekly 45 minute Sessions

First Posted Date: 2019-01-07

Last Posted Date: 2024-08-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT03794635

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Phase 2

Active, not recruiting

Conditions: Lymphoma
Leukemia

Interventions: Drug: CPI-613

First Posted Date: 2019-01-04

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03793140

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 8 locations

Continued Access to RXDX-105

Phase 1

Completed

Conditions: RET Gene Mutation
Ovarian Cancer
BRAF Gene Mutation
Non Small Cell Lung Cancer

Interventions: Drug: RXDX-105

First Posted Date: 2018-12-21

Last Posted Date: 2020-10-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03784378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Trial of IRE in Cholangiocarcinoma

Phase 2

Completed

Conditions: Cholangiocarcinoma

Interventions: Device: IRE Device

First Posted Date: 2018-12-07

Last Posted Date: 2022-09-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT03769753

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge (Consent and Follow up), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States

and more 4 locations

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Phase 2

Completed

Conditions: Multiple Myeloma
Diarrhea

Interventions: Drug: Colesevelam Pill

First Posted Date: 2018-12-06

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT03767257

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Early Phase 1

Completed

Conditions: EGFR Gene Mutation
Lung Cancer Metastatic
Lung Cancer

Interventions: Drug: Dacomitinib
Drug: Osimertinib

First Posted Date: 2018-11-27

Last Posted Date: 2023-07-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03755102

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Radiation: Re-irradiation (RT)
Drug: Bevacizumab
Drug: Nivolumab
Procedure: Re-resection

First Posted Date: 2018-11-16

Last Posted Date: 2024-08-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT03743662

Locations: 🇺🇸
Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania, United States
🇺🇸
University of Vermont Medical Center (Data Collection Only), Burlington, Vermont, United States
🇺🇸
Miami Cancer Institute Baptist Health South Florida (Data Collection Only), Miami, Florida, United States

and more 9 locations

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Phase 2

Active, not recruiting

Conditions: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Interventions: Drug: Pembrolizumab

First Posted Date: 2018-11-02

Last Posted Date: 2024-12-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT03728972

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy